Oxurion NV
Company

Oxurion NV

Biotechnology Research Leuven, Vlaams Brabant, Be 35 employees
Employees
35
Contacts
3
Emails
3

Oxurion NV Overview

Headquarters
Leuven, Vlaams Brabant, Be
Website
www.oxurion.com
Industry
Biotechnology Research
Employees
35
Funding
483.4K
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Oxurion NV

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Oxurion NV Contact Details

People in AeroLeads
4
With contact data
3
Email contacts
3
75.0% coverage

Oxurion NV Org Chart

Sample employees and titles
Name Title Contact
Johny Van Genechten Head of Global Ict at Thrombogenics Nv
View
Stijn Lagaert Partner, European & Belgian Patent
Email
Linda Knott Office Manager at Thrombogenics, Inc.
Email
Bert Tuerlinckx
Email

Employees by Management Level

VP / Head 1 profile
Manager 1 profile
Individual contributor 1 profile

Compare Similar Companies to Oxurion NV